Replies to post #133536 on Biotech Values

[NP1986]

ARRY had some limited and very early promising data on their drug but much larger and longer studies were needed and they don't have the resources for that. It's still available for partnering but I'm not holding out hope for anything.

Didn't they outlicense it to an Asian (Singaporean?) company, or am I thinking of something else?